- Home
- PPBT vs ONFO Comparison
PPBT vs ONFO Comparison
Compare PPBT & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- ONFO
- Stock Information
- Founded
- PPBT 2010
- ONFO 2018
- Country
- PPBT Israel
- ONFO United States
- Employees
- PPBT N/A
- ONFO N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- PPBT Health Care
- ONFO Technology
- Exchange
- PPBT Nasdaq
- ONFO Nasdaq
- Market Cap
- PPBT 6.2M
- ONFO 5.4M
- IPO Year
- PPBT N/A
- ONFO 2022
- Fundamental
- Price
- PPBT $2.33
- ONFO $1.31
- Analyst Decision
- PPBT Strong Buy
- ONFO
- Analyst Count
- PPBT 1
- ONFO 0
- Target Price
- PPBT $33.00
- ONFO N/A
- AVG Volume (30 Days)
- PPBT 251.5K
- ONFO 83.7K
- Earning Date
- PPBT 08-15-2025
- ONFO 08-13-2025
- Dividend Yield
- PPBT N/A
- ONFO N/A
- EPS Growth
- PPBT N/A
- ONFO N/A
- EPS
- PPBT N/A
- ONFO N/A
- Revenue
- PPBT N/A
- ONFO $9,087,118.00
- Revenue This Year
- PPBT N/A
- ONFO N/A
- Revenue Next Year
- PPBT N/A
- ONFO N/A
- P/E Ratio
- PPBT N/A
- ONFO N/A
- Revenue Growth
- PPBT N/A
- ONFO 65.97
- 52 Week Low
- PPBT $2.00
- ONFO $0.61
- 52 Week High
- PPBT $13.95
- ONFO $1.88
- Technical
- Relative Strength Index (RSI)
- PPBT 40.95
- ONFO 61.62
- Support Level
- PPBT $2.35
- ONFO $1.25
- Resistance Level
- PPBT $2.90
- ONFO $1.42
- Average True Range (ATR)
- PPBT 0.17
- ONFO 0.14
- MACD
- PPBT 0.00
- ONFO 0.02
- Stochastic Oscillator
- PPBT 13.29
- ONFO 64.81
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.